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Abstract

There is no consensus regarding optimal methodology for blood pressure monitoring in patients with a depressed ejection fraction
undergoing catheter ablation for atrial fibrillation. Our goals were to determine if hemodynamic management differences exist during
radiofrequency ablation for atrial fibrillation in patients with and without an ejection fraction< 50%, and whether management was influenced
by the utilization of invasive arterial blood pressure monitoring. This single-center trial retrospectively compared blood pressure management
during catheterablation of atrial fibrillationin all patients with an ejection fraction< 50% over a 2-year span (n=44), and compared to an agematched cohort with preserved ejection fraction ablated over the same span in time (n=44). Blood pressure was not significantly managed
differently between the groups, and did not appear to be influenced by the use of invasive arterial blood pressure monitoring. Hemodynamic
management is similar across the spectrum of ejection fraction, regardless of invasive arterial blood pressure monitoring, which challenges
the need for invasive arterial blood pressure monitoring during catheter ablation of atrial fibrillationin left ventricular systolic dysfunction.

Introduction

It has been over 15 years since the early description of catheter
ablation (CA) outcomes for atrial fibrillation (AF) in patients with left
ventricular systolic dysfunction (LVSD) 1. Subsequently, the results of
multiple studies 2-7, and most recently the Catheter Ablation Versus
Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction
(CAMERA-MRI) 8, Catheter Ablation for Atrial Fibrillation with
Heart Failure (CASTLE-AF) 9 and Effect of Catheter Ablation vs
Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and
Cardiac Arrest Among Patients with Atrial Fibrillation (CABANA)10
have suggested efficacy of catheter ablation (CA)for achieving normal
sinus rhythm in patients with AF and LVSD. None of these studies,
however, described the hemodynamic management during the
CA process. Also, current an esthesia recommendations and Heart
Rhythm Society guidelines are vagueregarding the subject of optimal
methodology for blood pressure monitoring in LVSD during CA
for AF11-13.We sought to determine if significant blood pressure
management differences exist between patients with and without
significant LVSD undergoing CA of AF, and whether management
was influenced by the use of invasive arterial blood pressure monitoring
(IABP).
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Materials and Methods

All patients with an EF< 50% undergoing CA for AF over a 2-year
span were included in the retrospective analysis. An age-matched
cohort with preserved EF (> 50%) also having CA for AF during the
same timeframe was included for comparison [Table 1].The study was
approved by the University of Kentucky institutional review board.
Pre-procedure, there was no discontinuation of guideline-directed or
advanced medical therapies for heart failure (including continuous
milrinone). Cessation of anti-arrhythmic drug therapy 5 days prior
occurred at the discretion of the attending electrophysiologist.
All CA procedures were performed after informed consent was
obtained, and under general anesthesia. The choice of inhaled anesthetic
(desflurane, isoflurane, sevoflurane) and paralytic agent (rocuronium,
succinylcholine, etomidate) was determined by the attending
anesthesiologist. Otherwise, propofol(150 mg) or dexmedetomidine (1
mcg/kg), lidocaine (50 mg) and fentanyl (100 mcg) single boluses were
also dosed at induction. Venous vascular access was obtained at all sites
with ultrasound guidance. All patients were also monitored with an
indwelling intracardiac echocardiography (ICE) catheter throughout
the CA. The method of blood pressure monitoring, invasive arterial
blood pressure (IABP) via a radial line versus a non-invasive cuff, was
also determined by anesthesia services. Vasopressor (VP) agents were
given for a 20% drop in mean arterial pressure (MAP) from baseline,
or to maintain MAP > 60 mmHg. VP dosing was charted at time of
occurrence. Choice of VP titration, continuous drip (phenylephrine
0.1-0.25 mcg/min or norepinephrine 2-4 mcg/min) and/or bolus
(ephedrine 5 mg, phenylephrine 100-200 mcg, and/or vasopressin 1
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Data Analysis

Specified data endpoints included procedure duration, percent
continuous IABP and VP utilization, number of VP interventions
per patient, time of VP intervention, time to first VP intervention,
minimum MAP (mMAP), average procedural urinary output > 100
ml/hour, length of stay, 30-day re-hospitalization, and longest time of
continuous intervention (LTCI). A VP intervention was an instance of
VP bolus in time or initiation/titration up or down of a VP drip. LTCI
was defined as the longest time of VP bolus and/or drip titration before
a 5 minute charting gap not requiring an intervention was reached.
The effect of IABP monitoring presence on number of interventions,
mMAP, and LTCI in the EF < 50% groups was also studied.

Statistical Analysis
Figure 1:

Effect of IABP in patients EF < 50%

unit) was determined by the attending physician/nurse anesthetist as
well. Intra-operative up-titration of milrinoneoccurred at the discretion
of the attending electrophysiologist. Vital signs were charted at least
every 5 minutes. All patients received a Foley catheter to monitor
urinary output.
Radiofrequency CA was accomplished with a 3.5 mm irrigated
tip catheter. This consisted of a wide circumferential isolation of all
pulmonary veins (left veins first followed by the right), then posterior
wall isolation for patients with persistent AF only, and ablation of
resultant or inducible atrial tachyarrhythmias in all patients. An intracardiac echocardiography catheter provided continuous monitoring
capabilities to address the presence of a pericardial effusion when
needed. An isoproterenol drip at 10 mcg/min was used during the
post-ablation induction process. Single doses of protamine 100 mg
and furosemide 60 mg were given intravenously once the study was
completed. All access sheaths were then removed. Hemostasis was
obtained via direct manual compression for an internal jugular venous
sheath, and a purse-string stitch with manual compression at both
groins. The endo-tracheal tube was removed at study completion in the
procedure room. Chest radiography(CXR) was ordered post-procedure
by advanced practice providers to rule out pneumothorax, and for other
clinical reasons on an individual basis.
Patients were recovered on a telemetry unit with planned discharge
home the next day. Near term follow-up consisted of a 1-week post
procedure phone call and 1-month office visit.

Statistical analysis included student’s t-test for comparison of
unpaired means, and Fisher’s exact for comparison of continuous
categorical variables. A p-value < 0.05 was considered statistically
significant.

Results

All patients had successful completion of the intended ablation.
There were no incidences of pericardial effusion or complications at
the vascular access sites. Additionally, ablation of induced or converted
rhythms (atrial flutter, atrial tachycardia, and typical atrio-ventricular
nodal reentry tachycardia) occurred and were most common in the
EF 7lt; 40% group; 70% (16/23), but not significantly more than the
EF 40-49%; 33% (7/21) or EF > 50%; 34% (15/44) groups. [Table
2] displays the results for the specified study endpoints. Other than
IABP utilization there were no significant differences among the study
groups. The presence of IABP monitoring [Figure 1] also did not
significantly influence the number of VP interventions, mMAP, or
LTCI. Use of a vasopressor drip [Table 3] was not different amongst
all groups. Its use significantly lessened the number of VP interventions
only within the EF 40-49% group, and had no significant impact
otherwise on mMAP or LTCI.
[Figure 2] shows the number of VP interventions with respect to
time during the ablation procedure. There appeared 3 distinct periods of
increased VP intervention, 0-95 minutes, 96-125 minutes, and 126-200
minutes. The most interventions in a single patient within a 5-minute
charting period was a single instance of 4, followed by 2 instances of 3.
These all occurred in patients with EF > 50% and no IABP monitoring.
Average hourly urinary output was > 100 ml/hour during the procedure
in 95% (42/44) of EF > 50%, 81% (17/21) of EF 40-49%, and 87%

Baseline Characteristics at Procedure Initiation

Table 1:
Group

n

% male

Age (y)

% Diuretic

% Anti-HTN

% DM or PN

% NSR

MAP (mmHg)

Mean HR (bpm)

EF ≥ 50%

44

66 (29/44)

62

25 (11/44)

80 (35/44)

25 (11/44)

59 (26/44)

99 +/- 18

82 +/- 25

EF < 50%

44

80 (35/44)

60

64 (28/44)

95 (42/44)

32 (14/44)

45 (20/44)

94 +/- 17

83 +/- 18

EF 40-49%

21

62 (13/21)

63†

33 (7/21)

90 (19/21)

43 (9/21)

38 (8/21)

99 +/- 17

86 +/- 18

EF < 40%

23

96 (22/23)

57†

91 (21/23)

100 (23/23)

22 (5/23)

52 (12/23)

90 +/- 16

80 +/- 19

EF 31-39%

6

100 (6/6)

56

100 (6/6)

100 (6/6)

0 (0/6)

33 (2/6)

85 +/- 12

81 +/- 25

EF 21-30%

10

90 (9/10)

48

80 (8/10)

100 (10/10)

40 (4/10)

70 (7/10)

87 +/- 13

76 +/- 20

EF ≤ 20%

7

100 (7/7)

63

100 (7/7)

100 (7/7)

14 (1/7)

42 (3/7)

100 +/- 16

84 +/- 11

DM = diabetes mellitus, HR = mean heart rate, HTN = hypertension, MAP = mean arterial pressure, NSR = normal sinus rhythm, PN = peripheral neuropathy
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Specified Procedure Outcomes

Table 2:
Group

Procedure Time (min.)

% IABP

% Needing VP

% VP Drip Use

Total # Interventions
(Int. per Patient)

Time to First Int. (min.)

mMAP (mmHg)

Mean LTCI (min.)

EF ≥ 50%

151

2 (1/44)* + †

80 (35/44)

29 (10/35)

221 (5)

34

58

12

EF < 50%

156

50 (22/44)*

95 (42/44)

50 (21/42)

276 (6)

32

61

13

EF 40-49%

157

24 (5/21)+

95 (20/21)

70 (14/20)

165 (8)

27

61

17

EF <40%

156

74 (17/23)†

96(22/23)

32 (7/22)

111 (5)

35

61

9

EF 31-39%

133

67 (4/6)

83 (5/6)

20 (1/5)

41 (7)

31

59

9

EF 21-30%

167

70 (7/10)

100 (10/10)

40 (4/10)

51 (5)

35

61

7

EF ≤ 20%

159

86 (6/7)

100 (7/7)

29 (2/7)

19 (3)

38

62

13

EF = ejection fraction, IABP = invasive arterial blood pressure, Int. = Intervention, LTCI = longest time of continuous intervention, mMAP = minimal mean arterial pressure, VP = vasopressor

(20/23) of EF < 40% groups (p=NS). All patients were extubated and
had complete discontinuation of VP drips before leaving the procedure
room. All patients except one in the EF 40-49%group (96%) were
recovered and monitored on a telemetry unit. The single exception
had transient complete heart block post ablation that resolved with
cessation of beta blockade by the next morning after intensive care
unit observation. Three EF < 40% patients (13%)required post-op
intervention for respiratory status before discharge the following day.
One was for subjective shortness of breath, mild vascular congestion
on CXR, and decreased oxygen saturation.
Management consisted of brief bi-level positive airway pressure and
a single intravenous dose of furosemide. Two patients had shortness of
breath, mild vascular congestion without edema on CXR, and received
a single dose of intravenous furosemide.
Length of stay was 1.3± 1.8 days in the EF > 50% group, 1.1± 0.5 days
in the EF 40-49%group and 1 day in the EF < 40% group (p=NS). A
single patient with EF > 50% (2%) had a pre-existing pacemaker system
issue that required management and a 13-day stay, and one EF 40-49%
patient (5%) had nausea and vomiting due to suboxone withdrawal
prompting a 3-day stay. Three patients each in the EF >50% (7%) and
< 50% (7%) groups were re-hospitalized within 30 days. One in each
group was for infection, one also in the EF 40-49% group for astroke
event presenting as confusion/dizziness (positive head CT scan), and
one in the EF < 40% group for hypokalemia. One patient in the EF
< 40% group had abdominal discomfort with shortness of breath and
was discharged from the emergency room following a brisk diuresis 4
days after their procedure.

for VP titration in the LVSD population. This is particularly relevant
to the overall safety of the process given that vascular issues are the
most frequently reported complication of CA for AF, albeit occurring
in only approximately 2% of cases14.The rate of major complication
from radial artery access is fortunately significantly less 15. A resultant
compartment syndrome, however, can be very devastating. The femoral
arterymay be also utilized for IABP monitoring as well for CA of AF,
and was not used in this study. Femoral access can contribute to the
incidence of pseudoaneurysm and AV fistula16.These complications can
be eliminated or minimized with use of non-invasive blood pressure
cuffs.
Three distinct periods of increased blood pressure intervention
were identified during the CA process in this study, each likely
with a different physiologic cause. The first period began shortly
after anesthesia induction and was likely due to a combination of
negative inotropy, attenuated sympathetic reflex, pre-load reduction,
and decreased vascular resistance 19-20.The second occurred when
programmed stimulation, linear lines for posterior wall isolation,
or rhythm conversion to atrial flutter were most common, likely
contributing to transient increased VP needs following pulmonary
vein isolation 21-22. VP interventions were more prominently seen in
the EF 40-49% group in this timeframe. Patients with heart failure
mid-range EF (HFmrEF) have been shown to have a large prevalence,
upwards of 76%, of diastolic dysfunction based on echo cardiographic
findings 23. Our mid-range EF group was not categorized HFmrEF

Discussion

In addition to efficacy, understanding safety is critical for wider
acceptance of CA for AF in LVSD by the general electrophysiology
community. To date, there is no study of CA for AF describing the
hemodynamic management and optimal methodology for blood
pressure monitoring, particularly in those with significant LVSD. This
study showed the hemodynamic management of a radiofrequency
CA procedure in a cohort of patents with EF < 50%under general
anesthesia to be similar to that of a preserved EF population. There was
no significant difference between groups for the specified hemodynamic
endpoints. IABP monitoring did not significantly affect the need for
VP interventions within EF 40-49% and EF <40% groups and when
they were compared to an EF > 50% group. Taken together our data are
also suggestive of the safety of non-invasive blood pressure monitoring

www.jafib.com

Figure 2:

Specified Procedure Outcomes.

EF = ejection fraction, IABP = invasive arterial blood pressure, Int. = Intervention, LTCI = longest
time of continuous intervention, mMAP = minimal mean arterial pressure, VP = vasopressor
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simply because we did not seek to establish the European Society of
Cardiology diagnostic criterion in this group 24. There does not appear
to be a consensus at this point whether this EF range represents a new
category of heart failure 25. However, the authors separately analyzed
this group to see if there were any hemodynamic differences detectable
in our process. It seems reasonable to assume that our EF 40-49%
group may have had some incidence of diastolic dysfunction to explain
the hemodynamic reaction during this timeframe. The third period of
escalation correlated with initiation of isoproterenol. The vasodilatory
effects of its beta-2 receptor actions may outweigh the beta-1 receptor
agonist increase in heart rate and contractility, thus causing a drop in
blood pressure 26. Each of the groups showed similar responses during
the active isoproterenol infusion and washout phase. Regardless, the
physiologic effects and the corrective actions in all 3 time periods, were
similarly experienced and efficiently managed in all groups regardless
of IABP use.
Overcorrection of hypotension from VP interventions did not appear
to be an issue as only one instance of intravenous beta blockade was
dosed for this reason in a patient receiving VP boluses in the 88 patient
study population. Otherwise, VP drips were titrated down without issue
to achieve the desired MAP.

Limitations

This study represents the non-randomized experience at a single
facility with modest sample size, using general anesthesia, and
radiofrequency energy. There were multiple anesthesia practitioners,
who were not dedicated cardiac specialists. As such, this likely
provided more variability in management choices, including the use
of IABP monitoring. Our results are also not necessarily applicable
to an alternate anesthesia strategy. Regardless, the patients were
safely attended within this construct resulting in similar management
whether or not IABP monitoring occurred.
Time to first VP intervention, number of interventions, mMAP,
average hourly urinary output > 100 ml/hr, and LTCI were chosen
as measures of hemodynamic tolerance by the investigators, and to
our knowledge have not been described before for this purpose. Their
validity may be questioned. These data endpoints, however, seemed a
reasonable means to describe blood pressure management within our
process.
Table 3: Effect of Vasopressor Drip Presence on Intervention Management
Group

# Interventions
(Int. per Patient)

p
value

Mean LTCI
(min.)

p
value

mMAP (mmHg)

p value

- Drip

+ Drip

- Drip

+ Drip

- Drip

+ Drip

EF >
50%
(n=35)

133
(5.3)

88
(8.8)

0.26

11

16

0.20

58

59

0.65

EF <
50%
(n=42)

175
(8.3)

101
(4.8)

0.13

12

13

0.64

60

61

0.50

EF
40-49%
(n=20)

96 (16)

69
(4.9)

0.03

20

16

0.25

58

61

0.47

EF <
40%
(n=22)

79 (15)

32
(4.6)

0.78

10

7

0.26

60

62

0.60

CA = catheter ablation, ICD = implantable cardioverter defibrillator, Q = every
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There were no incidences of tamponade and access site bleeding
in this study. This was likely due to operator experience, ultrasound
guidance and use of ICE for venous and transseptal access. As such it
is unclear from our results whether IABP would have been superior to
a non-invasive cuff for navigating such adverse events in those not as
experienced or utilizing ICE and ultrasound for access.

Conclusions

Hemodynamic management of CA for AF appears similarly
experienced in patients across the spectrum of EF. Blood pressure
interventions were handled in a timely fashion with and without IABP
monitoring. The need for increased VP intervention in the 3 groups in 3
distinct time periods was universal, and not influenced by the presence
of IABP monitoring. Based on our findings, vascular complications can
be further minimized with use of non-invasive cuffs for blood pressure
monitoring without sacrificing safety in the LVSD population in our
process. CA for AF, even in patients with Class IV chronic systolic
heart failure on ambulatory inotropic therapy, appears to be safe in the
hands of experienced practitioners. Further study will be required to
further address safety and efficacy in this group.
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